Cyclooxygenase-2 inhibitors in tumorigenesis (Part I)

Journal of the National Cancer Institute

Volumn 90, Issue 20, 1998, Pages 1529-1536

  Taketo, Makoto M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; 4' ACETYL 2' (2,4 DIFLUOROPHENOXY)METHANESULFONANILIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; AMINO ACID; ARACHIDONIC ACID; BL 2338; BL 2365; CGP 28232; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ENDOPEROXIDE; FENAMIC ACID DERIVATIVE; HYDROXYICOSATETRAENOIC ACID; MESSENGER RNA; MITOGENIC AGENT; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PEROXIDASE; PROPIONIC ACID DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROSTANOID; PYRAZOLE DERIVATIVE; RS 104879; RS 57067; SALICYLIC ACID DERIVATIVE; THROMBOXANE; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ARACHIDONIC ACID METABOLISM; CARCINOGENESIS; COLORECTAL CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; TUMOR;

EID: 0032556188     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.20.1529     Document Type: Review

References (98)

1. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 1996;87:803-9.
2. Marnett LJ. Aspirin and the potential role of prostaglandin in colon cancer. Cancer Res 1992;52:5575-89.
3. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:179-94.
4. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996;62:167-215.
5. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-91.
6. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
7. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997;11:234-47.
8. Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976;251:2629-36.
9. Hemler M, Lands WE. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 1976;251:5575-9.
10. Van der Ouderaa FJ, Buytenhek M, Nugteren DH, Van Dorp DA. Purification and characterization of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 1977;487:315-31.
11. Ogino N, Ohki S, Yamamoto S, Hayaishi O. Prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. Inactivation and activation by heme and other metalloporphyrins. J Biol Chem 1978;253: 5061-8.
12. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1986;55:69-102.
13. Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. Annu Rev Biochem 1975;44:669-95.
14. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978; 47:997-1029.
15. Pagels WR, Sachs RJ, Marnett LJ, Dewitt DL, Day JS, Smith WL. Immunochemical evidence for the involvement of prostaglandin H synthase in hydroperoxide-dependent oxidations by ram seminal vesicle microsomes. J Biol Chem 1983;258:6517-23.
16. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412-6.
17. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988;263:3550-3.
18. Yokoyama C, Takai T, Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 1988; 231:347-51.
19. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989;165:888-94.
20. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121-34.
21. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5: 2304-12.
22. Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993;307:361-8.
23. Shimokawa T, Smith WL. Essential histidines of prostaglandin endoperoxide synthase. His-309 is involved in heme binding. J Biol Chem 1991; 266:6168-73.
24. Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992;293:391-400.
25. Lin AH, Bienkowski MJ, Gorman RR. Regulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by platelet-derived growth factor. J Biol Chem 1989;264:17379-83.
26. Wong WY, DeWitt DL, Smith WL, Richards JS. Rapid induction of prostaglandin endoperoxide synthase in rat preovulatory follicles by luteinizing hormone and cAMP is blocked by inhibitors of transcription and translation. Mol Endocrinol 1989;3:1714-23.
27. Wong WY, Richards JS. Evidence for two antigenically distinct molecular weight variants of prostaglandin H synthase in the rat ovary. Mol Endocrinol 1991;5:1269-79.
28. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 1992;267:21438-45.
29. Rosen GD, Birkenmeier TM, Raz A, Holtzman MJ. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 1989;164:1358-65.
30. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
31. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
32. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
33. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89:4888-92.
34. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
35. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267: 4338-14.
36. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992;25:249-65.
37. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991;60:281-319.
38. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992;89:7384-8.
39. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cyctokines. J Biol Chem 1993; 268:9049-54.
40. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997;387:83-90.
41. Tazawa R, Xu XM, Wu KK, Wang LH. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994;203:190-9.
42. Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 1994;221:889-97.
43. Wen PZ, Warden C, Fletcher BS, Kujubu DA, Herschman HR, Lusis AL. Chromosomal organization of the inducible and constitutive prostaglandin synthase/cyclooxygenase genes in mouse. Genomics 1993;15:458-60.
44. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990;21(12 Suppl):IV12-IV23.
45. Weissman G. Aspirin. Sci Am 1991;264:84-9.
46. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
47. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975;72:3073-6.
48. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56:624-32.
49. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26:33-67.
50. Van Der Ouderaa FJ, Buytenhek M, Nugteren DH, Van Dorp DA. Acetylation of prostaglandin endoperoxide synthase with acetylsalicylic acid. Eur J Biochem 1980;109:1-8.
51. Mizuno K, Yamamoto S, Lands WE. Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities. Prostaglandins 1982;23:743-57.
52. Marshall PJ, Kulmacz RJ. Prostaglandin H synthase: distinct binding sites for cyclooxygenase and peroxidase substrates. Arch Biochem Biophys 1988;266:162-70.
53. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
54. O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994;45:245-54.
55. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
56. Barnett J, Chow J, Ives D, Chiou J, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994;1209:130-9.
57. Rome LH, Lands WE. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A 1975;72:4863-5.
58. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207-15.
59. Mancini JA, O'Neill GP, Bayly C, Vickers PJ. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett 1994;342: 33-7.
60. DeWitt DL, El-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, et al. The aspirin and heme-binding sites of ovine and murine proslaglandin endoperoxide synthases. J Biol Chem 1990;265:5192-8.
61. Percival MD, Ouelletm M, Vincent CJ, Yergey JA, Kennedy BP, O'Neill GP. Purification and characterization of recombinant human cyclooxygenase-2. Arch Biochem Biophys 1994;315:111-8.
62. Laneuville O, Breuer DK, Xu N, Huang ZH, Gage DA, Watson JT, et al. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-octadecatrienoic acids form alpha-linolenic acid. J Biol Chem 1995;270: 19330-6
63. Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 1983;22:4672-5.
64. Bozza PT, Payne JL, Morham SG, Langenbach R, Smithies O, Weller PF. Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. Proc Natl Acad Sci U S A 1996;93: 11091-6.
65. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9.
66. Ghosh S, Kopp E. The effect of sodium salicylate and aspirin on NF-kB. Science 1995;270:2017-9.
67. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90: 11693-7.
68. Vane JR, Botting RM. A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res 1995;23:41-8.
69. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86: 543-52.
70. Wong S, Lee SJ, Friesson MR 3d, Proch J, Miskowski TA, Rigby BS, et al. Antiarthritic profile of BF-389 - a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions 1992;37:90-8.
71. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-10.
72. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47: 55-9.
73. Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993;45:753-5.
74. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91: 3228-32.
75. Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-10.
76. Reitz DB, Li JJ, Norton MB, Reinhard EJ, Collins JT, Anderson GD, et al. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem 1994;37: 3878-81.
77. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91: 12013-7.
78. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor. L-745 337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995; 274:1531-7.
79. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997;121: 105-17.
80. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990;254:180-7.
81. Tsuji K, Nakamura K, Konishi N, Okumura H, Matsuo M. Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2′-phenoxy-methanesulfonanilide derivatives. Chem Pharm Bull 1992;40: 2399-409.
82. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors. Inflamm Res 1995;44:253-7.
83. Swinney DC, Mak AY, Barnett J, Ramesha CS. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J Biol Chem 1997;272:12393-8.
84. Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:243-9.
85. Blobel G. Intracellular protein topgenesis. Proc Natl Acad Sci U S A 1980; 77:1496-500.
86. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995;2:637-43.
87. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996;3:927-33.
88. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegemun RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-8.
89. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koholdt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996;271:15810-4.
90. Gierse JK, Hauser SD, Creely DP, Kololdt C, Rangwala SH, Isakson PC, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 1995;305(Pt 2):479-84.
91. Bhattacharyya DK, Lecomte M, Rieke CJ, Garavito RM, Smith WL. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxidase H synthase-1. J Biol Chem 1996;271:2179-84.
92. Loll PJ, Picot D, Ekabo P, Garavito RM. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996;35:7330-40.
93. Carty TJ, Stevens JS, Lombardino JG, Parry MJ, Randall MJ. Piroxicam, a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition. Prostaglandins 1980;19:671-82.
94. Bhattacharyya DK, Lecomte M, Dunn J, Morgans DJ, Smith WL. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicyclic acid. Arch Biochem Biophys 1995;317:19-24.
95. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A 1994;91:11202-6.
96. Setti-Carraro P, Nicholls RJ. Choice of prophylactic surgery for the large bowel compartment of familial adenomatous polyposis. Br J Surg 1996; 83:885-92.
97. Bendele AM, Ruterbories KJ, Spaethe SM, Benslay DN, Lindstrom TD, Lee SJ, et al. Correlation of anti-inflammatory activity with peak tissue rather than peak plasma levels of BF389. J Pharmacol Exp Ther 1992;260: 1194-8.
98. Morimoto K, Sugimoto Y, Katsuyama M, Oida H, Tsuboi K, Kishi K, et al. Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract. Am J Physiol 1997;272(3 Pt 1):G681-G687.